Total of 62 patients have been examined, out of which 34 patients had chronic catarrhal rhinitis, and 28 patients - perennial allergic rhinitis. It has been established that intranasal aerosol-therapy with cyclopheron induced expressed improvement of bronchial permeability in these patients, as well as increase of reserve possibilities of lungs and decrease, up to complete elimination, of arterial and venous hypoxemia. Above positive shifts were significant in chronic catarrhal rhinitis.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Targeted delivery of flagellin by nebulization offers optimized respiratory immunity and defense against pneumococcal pneumonia.
Antimicrob Agents Chemother
December 2024
Univ. Lille CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 9017 - CIIL - Center for Infection and Immunity of Lille, Lille, France.
Novel therapeutic strategies are urgently needed to combat pneumonia caused by strains resistant to standard-of-care antibiotics. Previous studies have shown that targeted stimulation of lung innate immune defenses through intranasal administration of the Toll-like receptor 5 agonist flagellin improves the treatment of pneumonia when combined with antibiotics. To promote translation to the clinic application, this study assessed the direct delivery of flagellin to the airways through nebulization using a vibrating mesh nebulizer in mice.
View Article and Find Full Text PDFHigh-Flow Nasal Aerosol Therapy; Regional Aerosol Deposition and Airway Responsiveness.
J Aerosol Med Pulm Drug Deliv
December 2024
Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, Stony Brook University Medical Center, Stony Brook, New York, USA.
Article Synopsis
- In a study involving 12 subjects with moderate to severe obstructive lung disease (OLD), researchers compared aerosol deposition and airway responsiveness using traditional nebulization and high-flow nasal cannula (HFNC) therapy.
- Results showed that while traditional inhalation resulted in a central to peripheral deposition ratio, the use of HFNC significantly increased peripheral drug delivery and improved spirometry measures, indicating better lung function.
- The study also noted that systemic effects were minimal, suggesting that nasal absorption of the aerosol medication was limited, and different mechanisms governed deposition when comparing traditional nebulization to HFNC methods.
Human inhalable antibody fragments neutralizing SARS-CoV-2 variants for COVID-19 therapy.
Mol Ther
May 2022
Alfasigma SpA, Biotechnology R&D, Via Pontina Km 30.400, Pomezia, 00071 Rome, Italy. Electronic address:
As of December 2021, coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), remains a global emergency, and novel therapeutics are urgently needed. Here we describe human single-chain variable fragment (scFv) antibodies (76clAbs) that block an epitope of the SARS-CoV-2 spike protein essential for ACE2-mediated entry into cells. 76clAbs neutralize the Delta variant and other variants being monitored (VBMs) and inhibit spike-mediated pulmonary cell-cell fusion, a critical feature of COVID-19 pathology.
View Article and Find Full Text PDFA narrative review on trans-nasal pulmonary aerosol delivery.
Crit Care
August 2020
Department of Medicine, University of Tennessee Graduate School of Medicine, Knoxville, TN, USA.
The use of trans-nasal pulmonary aerosol delivery via high-flow nasal cannula (HFNC) has expanded in recent years. However, various factors influencing aerosol delivery in this setting have not been precisely defined, and no consensus has emerged regarding the optimal techniques for aerosol delivery with HFNC. Based on a comprehensive literature search, we reviewed studies that assessed trans-nasal pulmonary aerosol delivery with HFNC by in vitro experiments, and in vivo, by radiolabeled, pharmacokinetic and pharmacodynamic studies.
View Article and Find Full Text PDFDevelopment of an Inline Dry Powder Inhaler for Oral or Trans-Nasal Aerosol Administration to Children.
J Aerosol Med Pulm Drug Deliv
April 2020
Department of Mechanical and Nuclear Engineering and Virginia Commonwealth University, Richmond, Virginia.
Dry powder inhalers (DPIs) offer a number of advantages, such as rapid delivery of high-dose inhaled medications; however, DPI use in children is often avoided due to low lung delivery efficiency and difficulty in operating the device. The objective of this study was to develop a high-efficiency inline DPI for administering aerosol therapy to children with the option of using either an oral or trans-nasal approach. An inline DPI was developed that consisted of hollow inlet and outlet capillaries, a powder chamber, and a nasal or oral interface.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!